Title
New Insulin Therapy by Multiwave Bolus
Evaluation of Insulin Therapy by Multiwave Bolus Based on the Lipid and Protein Content in Addition to the Carbohydrates Content Compared to Insulin Therapy Based Only on the Carbohydrates Content in type1 Diabetes Treated by Insulin Pump
Phase
N/ALead Sponsor
University of LorraineStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Type1diabetesIntervention/Treatment
New functional insulin therapy functional insulin therapyStudy Participants
150The aim of the study is to evaluate the effect of insulin therapy when the bolus dose of insulin is calculated on the basis of protein and fat content in food intake, in addition to that of carbohydrates in T1D patients treated by insulin pump. The study is planned to recruit 150 patients with type1 diabetes already practicing functional insulin therapy based on carbohydrate counting in meals. We will therefore study the effect on continuous glucose measured by subcutaneous sensor, of meal bolus adjustments by comparing two groups of T1D patients:
Groupe A takes into account the lipid and protein content in addition to the carbohydrate content
Group B takes into account the carbohydrate content only At randomization, all patients receive dietary and adjustment of bolus doses instructions according to the randomization group. They have to apply these instructions for 3 months. At the end of 3 months, the study groups will be under glucose monitoring during two weeks in the Outpatient Clinic but returns to the investigational site in hospital to download data from the continuous measurement of glucose. In addition, we propose a period of extension similar to that of the main period, namely 3 months of application of dietetic and adaptation of bolus doses instructions and 2 weeks of continuous measurement of glucose.
During each 2 weeks period will be assessed specific glucose parameters in the post-prandial period over 4hours (glycemic sensor values in the glucose range between 70-140 mg / dl, glycemic sensor values in the glucose range between 140 -180 mg /dl and > 180 mg /dl) after taking each meal during the 13 days of Glucose Continuous Measurement (GCM), average daily glucose per meal, average blood glucose over the 13-day period after each meal.
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
Inclusion Criteria: Type 1 diabetic patient for more than one year, practicing functional insulin for at least 3 months but not more than 5 years Patient treated with external insulin pump (Medtronic or Omnipod pump) Patient performing intermittent blood glucose monitoring by the continuous interstitial glucose measurement system (Freestyle Libre) and who regularly wears this device with an achievement of at least 4 scans per day to obtain at least 90% of the possible values Patient with HbA1c ≤10.0% less than 3 months Patient with a willingness and ability to comply with study requirements and schedule of visits Patient who received complete information and signed informed consent Exclusion Criteria: Patient with contraindication for rapid or ultra-rapid insulin analogues Patient for whom a change of insulin in the next 3 to 6 months is planned Women of childbearing age who do not have effective contraception Women who are pregnant or breast feeding or plan on becoming pregnant during the study Patient taking medication that interferes with interpretation of study results such as chronic corticosteroid therapy Patient with a chimio - or radiotherapy is in progress or is planned Patient abusing substances Patient who participated in another clinical study in the four weeks prior to inclusion Patient with or suspected of having any physical, psychological or cognitive disorders interfering with adherence to insulin therapy by pump, or compliance with dietary advice, or completion of the patient's diary Patient unable to comply with clinical guidelines, and unable to comply with 3-month follow-up Patient unable to understand information, to sign informed consent or to manage glycemic sensor
